本文關(guān)鍵詞：疏肝解郁化積法治療惡性腫瘤相關(guān)性抑郁綜合征臨床研究　出處：《山東中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 惡性腫瘤 抑郁綜合征 生活質(zhì)量 中醫(yī)治療

【摘要】：目的以“疏肝解郁化積”為法,組方“疏肝解郁化積方”干預(yù)治療惡性腫瘤相關(guān)性抑郁綜合征,觀察其臨床療效及對患者生活質(zhì)量的影響,提高癌癥患者生存質(zhì)量。對中西醫(yī)綜合干預(yù)治療惡性腫瘤相關(guān)性抑郁綜合征提供更多方法。方法于2015年01月至2016年01月期間就診于山東中醫(yī)藥大學(xué)東附屬醫(yī)院腫瘤科門診的惡性腫瘤患者中,選取符合本研究納入標(biāo)準(zhǔn)的60例患者,采用隨機(jī)對照試驗(yàn)的方法,分為西藥組:給予口服百優(yōu)解20mg/日;中藥組:給予“疏肝解郁化積方”,中藥水煎服,日一劑;兩組均持續(xù)6周治療,于治療前后采集臨床數(shù)據(jù)。觀察所有入組患者治療效果差異。用SPSS19統(tǒng)計(jì)軟件進(jìn)行數(shù)據(jù)統(tǒng)計(jì)分析,統(tǒng)計(jì)數(shù)據(jù)以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示。組間比較采用秩和檢驗(yàn),組內(nèi)比較采用配對t檢驗(yàn),P0.05表示有統(tǒng)計(jì)學(xué)意義。結(jié)果1、西藥組經(jīng)治療后總體有效率為56.67%,中藥組總體有效率為63.33%。兩組之間無統(tǒng)計(jì)學(xué)差異(P0.05)。2、治療前后HAMD積分比較,經(jīng)t檢驗(yàn),中藥組與西藥組治療前后HAMD積分具有統(tǒng)計(jì)學(xué)意義(P0.05)。經(jīng)t檢驗(yàn),兩組之間對比,無統(tǒng)計(jì)學(xué)意義(P0.05)。表明兩組在改善患者HAMD積分上,二者無顯著差異。3、治療前后SERS積分比較,經(jīng)t檢驗(yàn),中藥組治療前后及兩組之間SERS積分具有統(tǒng)計(jì)學(xué)意義(P0.05)。西藥組治療前后差異無統(tǒng)計(jì)學(xué)意義(P0.05)。表明中藥組較西藥組在治療中具有較低的治療副作用。4、治療前QLQ-C30整體生活質(zhì)量、癥狀量表、功能領(lǐng)域各維度得分與參考值比較顯示提示惡性腫瘤相關(guān)性抑郁在各維度使患者生活質(zhì)量不同程度的下降。中藥組治療前與治療后比較,失眠、食欲減退、便秘、疼痛、惡心嘔吐、疲乏及情緒功能領(lǐng)域數(shù)據(jù)有顯著性差異(P0.05)。其他領(lǐng)域無顯著性差異(P0.05)。見表6。西藥組治療前與治療后比較,失眠、腹瀉、惡心嘔吐及情緒功能領(lǐng)域數(shù)據(jù)有顯著性差異(P0.05)。其他領(lǐng)域無顯著性差異(P0.05)。見表7。表明中藥組治療在改善患者癥狀,提高患者生活質(zhì)量方面,優(yōu)于西藥組。并具有較低的副作用。結(jié)論中藥組與西藥組在治療惡性腫瘤相關(guān)性抑郁綜合征的總體臨床療效及改善HAMD積分上無明顯差異;中藥組在改善患者QLQ-C30積分上優(yōu)于西藥組,中藥組較西藥組在治療中具有較低的治療副作用。以“疏肝解郁化積”法組方能在一定程度上提高患者生活質(zhì)量,降低治療帶來的副反應(yīng)。為中醫(yī)治療腫瘤相關(guān)性抑郁綜合征提供了新方法。值得進(jìn)一步研究與推廣。
[Abstract]:Objective to observe the clinical effect and quality of life of patients with malignant tumor-associated depression syndrome treated by "Shugan Jieyu Huazhi prescription". To improve the quality of life of cancer patients. To provide more methods for the treatment of malignant tumor-associated depression syndrome by comprehensive intervention of traditional Chinese and western medicine. Methods from January 2015 to January 2016, we visited Shandong traditional Chinese Medicine. Malignant tumor patients in the Department of Oncology, East affiliated Hospital of the University. Sixty patients who met the criteria of this study were selected and divided into western medicine group by randomized controlled trial. Traditional Chinese medicine group: "Shugan Jieyu Huazhi prescription", traditional Chinese medicine decoction of water, a daily dose; The two groups were treated for 6 weeks. The clinical data were collected before and after the treatment. The difference of treatment effect between all the patients was observed. The data were analyzed by SPSS19 software. The statistical data were expressed as mean 鹵standard deviation x 鹵s. Rank sum test was used for inter-group comparison and pairing t test (P0.05) was used for intra-group comparison. Results 1. The total effective rate was 56.67 in the western medicine group and 63.33 in the traditional Chinese medicine group. There was no statistical difference between the two groups (P0.05. 2). The HAMD score was compared before and after treatment. After t test, the HAMD score of Chinese medicine group and western medicine group was statistically significant before and after treatment (P 0.05). After t test, there was a comparison between the two groups. There was no significant difference between the two groups in improving the HAMD score of the patients. There was no significant difference between the two groups. The SERS scores were compared before and after treatment by t test. The SERS score of the Chinese medicine group before and after treatment and between the two groups was statistically significant (P 0.05), but there was no significant difference before and after treatment in the western medicine group (P 0.05). The results showed that the traditional Chinese medicine group had lower side effects than the western medicine group. Before treatment, QLQ-C30 overall quality of life, symptom scale. The scores of each dimension and reference value in the functional field showed that the quality of life of patients with malignant tumor-related depression decreased in different degrees in each dimension. Before and after treatment, insomnia and loss of appetite were found in the traditional Chinese medicine group. Constipation, pain, nausea and vomiting. There was significant difference in the data of fatigue and emotional function (P 0.05). There was no significant difference in other fields (P 0.05). See Table 6.Compared before and after treatment, insomnia and diarrhea in the western medicine group. There was significant difference in the data of nausea and vomiting and emotional function (P 0.05). There was no significant difference in other fields (P 0.05). See Table 7. Improve the quality of life of patients. Conclusion there is no significant difference between the Chinese medicine group and the western medicine group in the overall clinical efficacy and the improvement of HAMD score in the treatment of malignant tumor-associated depression syndrome. The Chinese medicine group was superior to the western medicine group in improving the QLQ-C30 score of the patients. The traditional Chinese medicine group has lower side effects than the western medicine group. To a certain extent, it can improve the quality of life of the patients. It provides a new method for the treatment of tumor-associated depression syndrome by traditional Chinese medicine. It is worthy of further study and promotion.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R273

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐明;;參芪扶正注射液聯(lián)合順鉑治療肺癌惡性胸腔積液臨床研究[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2016年03期

2 沈潤;何洪生;梁彩霞;;艾迪注射液配合化療對惡性腫瘤化療患者生活質(zhì)量及抑郁的影響[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2015年34期

3 趙瑛;黃璞;史琛;伍三蘭;于麗秀;陳春生;;參芪扶正注射液上市后安全性的監(jiān)測研究[J];中國臨床藥理學(xué)雜志;2015年18期

4 胡洪;陳功;;中國惡性腫瘤患者抑郁患病率及其相關(guān)因素的研究[J];中國腫瘤臨床與康復(fù);2015年08期

5 徐霜;孫向紅;;米氮平對提高中重度抑郁的惡性腫瘤患者生活質(zhì)量的臨床觀察[J];中國醫(yī)科大學(xué)學(xué)報(bào);2015年08期

6 張健;張瑞光;蔡茜;陳玲娟;董繼華;伍鋼;董曉榮;;參芪扶正注射液對放射性腦損傷保護(hù)的分子機(jī)制探討[J];中華放射醫(yī)學(xué)與防護(hù)雜志;2015年06期

7 林文盛;陳劍英;程文桃;羅蘭珠;李凌恩;郭少楠;高明;鄭典誠;;米氮平治療抑郁癥患者體重變化與療效的相關(guān)性研究[J];海峽藥學(xué);2015年04期

8 李寧;楊渤彥;吳曉明;吳艷芳;王延風(fēng);徐海燕;于雷;;抗抑郁藥物聯(lián)合阿片類藥物和心理干預(yù)治療晚期癌痛伴抑郁的療效觀察[J];中國腫瘤臨床與康復(fù);2014年06期

9 唐夢莎;胡鴻;王國平;國實(shí);王德斌;;心理干預(yù)對中國惡性腫瘤患者生活質(zhì)量影響的Meta分析[J];中國衛(wèi)生事業(yè)管理;2014年05期

10 潘巍;孫海;王守華;涂燕玲;付金萍;徐樂;;氟西汀聯(lián)合同步放化療治療局部晚期非小細(xì)胞肺癌的臨床觀察[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年03期

，

本文編號：1434833